Open Access

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial

  • Authors:
    • Morena Antonilli
    • Hassan Rahimi
    • Valeria Visconti
    • Chiara Napoletano
    • Ilary Ruscito
    • Ilaria Grazia Zizzari
    • Salvatore Caponnetto
    • Giacomo Barchiesi
    • Roberta Iadarola
    • Luca Pierelli
    • Aurelia Rughetti
    • Filippo Bellati
    • Pierluigi Benedetti Panici
    • Marianna Nuti
  • View Affiliations

  • Published online on: February 8, 2016     https://doi.org/10.3892/ijo.2016.3386
  • Pages: 1369-1378
  • Copyright: © Antonilli et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Vaccination with priming and expansion of tumour reacting T cells is an important therapeutic option to be used in combination with novel checkpoint inhibitors to increase the specificity of the T cell infiltrate and the efficacy of the treatment. In this phase I/II study, 14 high-risk disease-free ovarian (OC) and breast cancer (BC) patients after completion of standard therapies were vaccinated with MUC1, ErbB2 and carcinoembryonic antigen (CEA) HLA-A2+-restricted peptides and Montanide. Patients were subjected to 6 doses of vaccine every two weeks and a recall dose after 3 months. ECOG grade 2 toxicity was observed at the injection site. Eight out of 14 patients showed specific CD8+ T cells to at least one antigen. None of 4 patients vaccinated for compassionate use showed a CD8 activation. An OC patient who suffered from a lymph nodal recurrence, showed specific anti-ErbB2 CD8+ T cells in the bulky aortic lymph nodes suggesting homing of the activated T cells. Results confirm that peptide vaccination strategy is feasible, safe and well tolerated. In particular OC patients appear to show a higher response rate compared to BC patients. Vaccination generates a long-lasting immune response, which is strongly enhanced by recall administrations. The clinical outcome of patients enrolled in the trial appears favourable, having registered no deceased patients with a minimum follow-up of 8 years. These promising data, in line with the results of similar studies, the high compliance of patients observed and the favourable toxicity profile, support future trials of peptide vaccination in clinically disease-free patients who have completed standard treatments.

References

1 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, et al; 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 17:2341–2354. 1999.PubMed/NCBI

3 

Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM and Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003. View Article : Google Scholar : PubMed/NCBI

4 

Paik S, Kim C and Wolmark N: HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med. 358:1409–1411. 2008. View Article : Google Scholar : PubMed/NCBI

5 

Aydiner A and Tas F: Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer. Trials. 9:472008. View Article : Google Scholar : PubMed/NCBI

6 

Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O and Conte P; After 6 Italian Cooperative Group. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: Final results of the After-6 protocol 1. J Clin Oncol. 27:4642–4648. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI

8 

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 10:942–949. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Napoletano C, Bellati F, Landi R, Pauselli S, Marchetti C, Visconti V, Sale P, Liberati M, Rughetti A, Frati L, et al: Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med. 14:2748–2759. 2010. View Article : Google Scholar

11 

Bellati F, Napoletano C, Ruscito I, Visconti V, Antonilli M, Gasparri ML, Zizzari IG, Rahimi H, Palaia I, Rughetti A, et al: Past, present and future strategies of immunotherapy in gynecological malignancies. Curr Mol Med. 13:648–669. 2013. View Article : Google Scholar

12 

Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S and Peoples GE: Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol Immunother. 56:135–146. 2007. View Article : Google Scholar

13 

Tsuruma T, Iwayama Y, Ohmura T, Katsuramaki T, Hata F, Furuhata T, Yamaguchi K, Kimura Y, Torigoe T, Toyota N, et al: Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med. 6:242008. View Article : Google Scholar : PubMed/NCBI

14 

Yuan J, Gallardo HF, Rasalan T, Ranganathan R, Wang J, Zhang Y, Panageas K, Stan R, Young JW, Houghton AN, et al: In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring. Cytotherapy. 8:498–508. 2006. View Article : Google Scholar

15 

Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ and Grady C: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 352:895–904. 2005. View Article : Google Scholar : PubMed/NCBI

16 

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI

17 

Thayer AM: Improving peptides. Chem Eng News. 89:13–20. 2011.

18 

Borghouts C, Kunz C and Groner B: Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci. 11:713–726. 2005. View Article : Google Scholar : PubMed/NCBI

19 

Gao GF and Jakobsen BK: Molecular interactions of coreceptor CD8 and MHC class I: The molecular basis for functional co-ordination with the T-cell receptor. Immunol Today. 21:630–636. 2000. View Article : Google Scholar : PubMed/NCBI

20 

Cho HI and Celis E: Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res. 69:9012–9019. 2009. View Article : Google Scholar : PubMed/NCBI

21 

Napoletano C, Rughetti A, Landi R, Pinto D, Bellati F, Rahimi H, Spinelli GP, Pauselli S, Sale P, Dolo V, et al: Immunogenicity of allo-vesicle carrying ERBB2 tumor antigen for dendritic cell-based anti-tumor immunotherapy. Int J Immunopathol Pharmacol. 22:647–658. 2009.PubMed/NCBI

22 

Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL and Schiffman K: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 20:2624–2632. 2002. View Article : Google Scholar : PubMed/NCBI

23 

Musselli C, Ragupathi G, Gilewski T, Panageas KS, Spinat Y and Livingston PO: Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int J Cancer. 97:660–667. 2002. View Article : Google Scholar : PubMed/NCBI

24 

Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L and Livingston PO: Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res. 6:1693–1701. 2000.PubMed/NCBI

25 

Knutson KL, Schiffman K, Cheever MA and Disis ML: Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, 369–377 results in short-lived peptide-specific immunity. Clin Cancer Res. 8:1014–1018. 2002.PubMed/NCBI

26 

Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K and Disis ML: Immunization of cancer patients with HER-2/neu-derived peptides demonstrating highaffinity binding to multiple class II alleles. Clin Cancer Res. 9:5559–5565. 2003.PubMed/NCBI

27 

Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG and Ponniah S: Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol. 23:7536–7545. 2005. View Article : Google Scholar : PubMed/NCBI

28 

Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, et al: Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci USA. 104:12837–12842. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, et al: Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 18:6497–6508. 2012. View Article : Google Scholar : PubMed/NCBI

30 

Hato SV, Khong A, de Vries IJ and Lesterhuis WJ: Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 20:2831–2837. 2014. View Article : Google Scholar : PubMed/NCBI

31 

Hato SV, de Vries IJ and Lesterhuis WJ: STATing the importance of immune modulation by platinum chemotherapeutics. OncoImmunology. 1:234–236. 2012. View Article : Google Scholar : PubMed/NCBI

32 

Diaz Y, Tundidor Y, Lopez A and Leon K: Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response. Cancer Immunol Immunother. 62:455–469. 2013. View Article : Google Scholar

Related Articles

Journal Cover

April 2016
Volume 48 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Antonilli, M., Rahimi, H., Visconti, V., Napoletano, C., Ruscito, I., Zizzari, I.G. ... Nuti, M. (2016). Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology, 48, 1369-1378. https://doi.org/10.3892/ijo.2016.3386
MLA
Antonilli, M., Rahimi, H., Visconti, V., Napoletano, C., Ruscito, I., Zizzari, I. G., Caponnetto, S., Barchiesi, G., Iadarola, R., Pierelli, L., Rughetti, A., Bellati, F., Panici, P. B., Nuti, M."Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial". International Journal of Oncology 48.4 (2016): 1369-1378.
Chicago
Antonilli, M., Rahimi, H., Visconti, V., Napoletano, C., Ruscito, I., Zizzari, I. G., Caponnetto, S., Barchiesi, G., Iadarola, R., Pierelli, L., Rughetti, A., Bellati, F., Panici, P. B., Nuti, M."Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial". International Journal of Oncology 48, no. 4 (2016): 1369-1378. https://doi.org/10.3892/ijo.2016.3386